A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device. Medical professionals in the United States have utilized the Gen-1 device to administer treatment to patients in clinical settings.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 157K | - | - | 1.3M | - |
| Net Income | -8.7M | -7.6M | -4.6M | -1.7M | -6.1M |
| EPS | $-0.65 | $-0.83 | $-0.63 | $-0.30 | $-1.25 |
| Free Cash Flow | 0 | -3.9M | -3.8M | -2.2M | -1.1M |
| ROIC | -1682.3% | -166.7% | -593.5% | -31.0% | -630.8% |
| Gross Margin | 69.5% | - | - | 72.5% | - |
| Debt/Equity | 0.00 | 0.15 | 0.16 | 0.09 | -0.30 |
| Dividends/Share | $0.00 | $0.00 | - | - | $0.00 |
| Operating Income | -8.9M | -7.8M | -5.7M | -1.8M | -6.0M |
| Operating Margin | -5641.4% | - | - | -138.7% | - |
| ROE | -182.0% | -221.1% | -145.0% | -89.4% | - |
| Shares Outstanding | 19M | 9M | 18M | 6M | 5M |
| Metric | 2021 | 2022 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | 1.3M | N/A | N/A | 157K |
| Gross Margin | N/A | 72.5% | N/A | N/A | 69.5% |
| R&D | 139K | 511K | 1.9M | 1.2M | 2.0M |
| SG&A | 5.2M | 1.5M | 1.9M | 4.2M | 4.1M |
| EBIT | -6.0M | -1.8M | -5.7M | -7.8M | -8.9M |
| Op. Margin | N/A | -138.7% | N/A | N/A | -5641.4% |
| Net Income | -6.1M | -1.7M | -4.6M | -7.6M | -8.7M |
| Net Margin | N/A | -128.5% | N/A | N/A | -5530.4% |
| Non-Recurring | 0 | 20K | 238K | 130K | 137K |
| Returns on Capital | |||||
| ROIC | N/M | -31.0% | N/M | -166.7% | N/M |
| ROE | N/A | -89.4% | -145.0% | -221.1% | -182.0% |
| ROA | -449.4% | -41.5% | -128.0% | -193.7% | -169.3% |
| Cash Flow | |||||
| Op. Cash Flow | -1.1M | -2.2M | -3.8M | -3.9M | -4.9M |
| Free Cash Flow | -1.1M | -2.2M | -3.8M | -3.9M | 0 |
| Owner Earnings | -5.6M | -2.5M | -6.2M | -7.5M | -8.8M |
| CapEx | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 30K | 2K | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | 0 |
| D&A | 30K | 2K | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 4.5M | 271K | 2.4M | 3.6M | 3.8M |
| Debt Repayment | 10K | 27K | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | -162K | -6.5M | -2.4M | N/A | -4.4M |
| Cash & Equiv. | 662K | 163K | 580K | 574K | 4.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.30 | 0.09 | 0.16 | 0.15 | 0.00 |
| Interest Coverage | -73.1 | -30.9 | -146.7 | -2428.6 | -2428.6 |
| Equity | -1.7M | 5.5M | 3.2M | 3.7M | 4.8M |
| Total Assets | 754K | 7.4M | 3.6M | 4.2M | 5.1M |
| Total Liabilities | 2.4M | 2.0M | 425K | 547K | 358K |
| Intangibles | N/A | N/A | 106K | 261K | 309K |
| Retained Earnings | -71M | -72M | -77M | -85M | -90M |
| Working Capital | -1.6M | 5.5M | 3.0M | 3.4M | 4.5M |
| Current Assets | 753K | 7.4M | 3.4M | 4.0M | 4.8M |
| Current Liabilities | 2.4M | 1.9M | 425K | 547K | 358K |
| Per Share Data | |||||
| EPS | -1.25 | -0.30 | -0.63 | -0.83 | -0.65 |
| Owner EPS | -1.14 | -0.44 | -0.35 | -0.82 | -0.47 |
| Book Value | -0.34 | 0.97 | 0.18 | 0.40 | 0.26 |
| Cash Flow/Share | -0.22 | -0.39 | -0.22 | -0.43 | -0.47 |
| Dividends/Share | 0.00 | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 4.9M | 5.7M | 17.6M | 9.2M | 18.7M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -0.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.8 | 0.9 | N/A | 1.7 |
| Price/Sales | N/A | 6.5 | N/A | N/A | 51.1 |
| FCF Yield | N/A | -52.4% | -129.3% | N/A | N/A |
| Market Cap | 0 | 4.2M | 3.0M | 0 | 8.0M |
| Avg. Price | 0.00 | 1.53 | 0.70 | 0.00 | 0.43 |
| Year-End Price | 0.00 | 0.75 | 0.40 | 0.00 | 0.43 |
Nexalin Technology, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 72.5%.
Nexalin Technology, Inc. (NXL) has a 5-year average return on invested capital (ROIC) of -98.8%. This is below average and may indicate limited pricing power.
Nexalin Technology, Inc. (NXL) has a market capitalization of $8M. It is classified as a small-cap stock.
Nexalin Technology, Inc. (NXL) does not currently pay a regular dividend.
Nexalin Technology, Inc. (NXL) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Nexalin Technology, Inc. (NXL) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Nexalin Technology, Inc. (NXL) has a debt-to-equity ratio of 0.15. This indicates a conservatively financed balance sheet.
Nexalin Technology, Inc. (NXL) reported earnings per share (EPS) of $-0.83 in its most recent fiscal year.
Nexalin Technology, Inc. (NXL) has a return on equity (ROE) of -221.1%. A negative ROE may indicate losses or negative equity.
Nexalin Technology, Inc. (NXL) has a 5-year average gross margin of 72.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 4 years of financial data for Nexalin Technology, Inc. (NXL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Nexalin Technology, Inc. (NXL) has a book value per share of $0.40, based on its most recent annual SEC filing.